ESC 2022 | INVICTUS and PRE18FFIR

On the 3erd day of the European Cardiology Congress 2022 the INVICTUS study was presented, including 4565 patients with atrial fibrillation secondary to rheumatism driven CAD. The aim of this study was to compare the use of Rivaroxaban vs vitamin K antagonists (VKA) in this populations. Mean age was 50 and most patients were women. 

ESC 2022

Primary end point was stroke, systemic thromboembolism, AMI, or cardiovascular death. Study outcomes resulted in 560 primary end point events in the rivaroxaban group vs 446 events in the VKA group (HR 1.25; 95% CI 1.10-1.41). On individual analysis, Rivaroxaban increased the risk of death by 23% and stroke by 37%. However, there were no differences in risk of bleeding between the groups. Drug discontinuation was more frequent in the Rivaroxaban group. 

Among rivaroxaban patients, when looking at RIN valued before study kickoff, within therapeutic range, it was 33%, and at follow-up, it reached 64% in 4 years. 

The use of vitamin K antagonists should be the standard treatment for rheumatic atrial fibrillation. We need further study to properly assess the different therapies for this special population. 

On the other hand, a multicenter prospective study was presented, the PRE18FFIR, which used sodium fluoride positron emission tomography scan (PET) to identify vulnerable plaque without the need for intravascular ultrasound imaging, predicting the risk of future cardiovascular events. 704 AMI and multivessel patients were included. They all received PET and coronary CT angiography and were followed up to 2 years. 

Read also: ESC 2022 | SECURE Trial.

There were no differences between patients with active coronary microcalcification and those who did not present any. However, when looking at cardiovascular death or AMI, events rate was higher among patients with positive PET imaging for CMA. 

This study shows an important role for PET in the assessment of cardiovascular risk. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting, there is uncertainty as to prolonging dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....